HOME >> BIOLOGY >> NEWS
Other highlights in the July 7 JNCI

Study Evaluates Design of Phase I Trials for Targeted Cancer Drugs

One purpose of a phase I clinical trial of a new cytotoxic drug is to determine the side effects associated with increasing drug dose, i.e., determine the dose that produces the maximum effect at which the toxicity can still be tolerated. New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to this paradigm because they can achieve their maximum effect at levels lower than the maximum tolerated dose.

In a new study, Wendy R. Parulekar, M.D., and Elizabeth A. Eisenhauer, M.D., of Queen's University in Kingston, Ontario, reviewed endpoints used in 60 published phase I studies of targeted, non-cytotoxic anticancer agents. They found that the majority of studies used the traditional endpoint of toxicity to determine the recommended dose for the phase II trials. Nontraditional endpoints, such as measures of molecular drug effects in tumor or surrogate tissue or functional imaging studies, were not routinely incorporated into the study design and rarely formed the primary basis for dose selection.

The authors conclude that although phase I studies of targeted anticancer agents in general continue to use traditional endpoints for selection of the recommended phase II dose, suitable molecular measures of drug effect and the means to incorporate them in the early drug development process are needed to optimize dose selection and drug development strategies.

In an editorial, Edward L. Korn, Ph.D., of the National Cancer Institute, discusses the assumptions and considerations required for choosing an endpoint in a phase I trial of a cytotoxic agent, and the challenges in using nontraditional endpoints for the dose selection of targeted, non-cytotoxic agents.

Contact: Wendy Parulekar, Queen's University, wparulekar@ctg.queensu.ca


Possible T
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
6-Jul-2004


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the June 16 JNCI
5. Other Highlights in the June 2 JNCI
6. Other highlights in the May 19 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2019)... (PRWEB) , ... April 23, 2019 , ... ... cancers have been acknowledged in the scientific literature. However, in many cases the ... Children and adolescents present a particularly challenging population, given neurocognitive effects may impact ...
(Date:4/25/2019)... Ohio (PRWEB) , ... April 25, 2019 , ... ... agents, as well as screening tools, has strengthened its commitment to meeting today’s ... be used in any application where inhibition of its targeted proteases is needed. ...
(Date:4/17/2019)... ... 17, 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, Vice ... for Creating a Sustainable Global UDI Compliance Strategy at the European UDI Forum on ... , What device manufacturers did to comply with the US FDA UDI rule ...
Breaking Biology News(10 mins):
(Date:5/2/2019)... ... April 30, 2019 , ... The centuries old practice of ... breweries to local craft breweries, and even home brewing clubs scattered across the nation. ... biological processes, that when mastered can produce a superb product. Students at South ...
(Date:5/2/2019)... (PRWEB) , ... May 02, 2019 , ... ... transplantation clinic in the greater Boston area. Gone are the days of painful ... ARTAS® iX Robotic Hair Restoration System is the only robotic intelligent solution to ...
(Date:4/18/2019)... Mass. (PRWEB) , ... April 18, 2019 , ... ... fossil fuels, a research team that includes a chemical engineer at Worcester Polytechnic ... exotic microorganism that may make it possible to manufacture isobutanol and other biofuels ...
(Date:4/15/2019)... LOVELAND, Ohio (PRWEB) , ... April 15, 2019 ... ... and oligomers, has completed construction of a $2 million bench plant expansion to ... represents an important step in the design and construction of Sirrus’ full-scale production ...
Breaking Biology Technology:
Cached News: